Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Itolizumab in Dermatomyositis
NCT05986162Phase 1Unknown
- Start
- Dec 2023
- Primary completion
- May 2025
- Modality
- Monoclonal Antibodies
01
Overview
Phase 1, randomised, open-label trial of itolizumab in dermatomyositis (DM) (3 arms). Primary endpoint: Incidence of Treatment Emergent Adverse Events at 20 weeks. Status: unknown.
02
Drugs
itolizumab
03
Conditions
dermatomyositis (DM)
Beyond the preview
Go deeper on NCT05986162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05986162.